Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Eli Lilly's corresponding weight-loss drugs to Novo Nordisk's obesity drug Wegovy and diabetes treatment Ozempic are Zepbound and Mounjaro, positioning the firm as a major rival to the Danish ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an ...

Recently, Novo Nordisk revealed trial results for two new obesity drugs, CagriSema and Amycretin. The former disappointed investors with less-than-projected weight loss, resulting in ... are now ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Next: Access Our New, Shockingly Simple 'Alert System' When evaluating the effects of treatment ... Also Read: Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss In interviews ...

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

Novo Nordisk A/S dominates in diabetes ... of treatment if all people adhered to treatment, amycretin demonstrated an estimated body weight loss of 9.7% on 1.25 mg (20 weeks), 16.2% on 5 mg ...